Medicine
ATNAA atropine and pralidoxime chloride Auto-Injector kit
ATNAA atropine and pralidoxime chloride Auto-Injector kit is a prescription medicine containing Atropine and Pralidoxime for intramuscular use, marketed by Meridian Medical Technologies, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage as on the product label
Key facts
- Active ingredient (INN)
- Atropine and Pralidoxime
- Brand
- ATNAA atropine and pralidoxime chloride Auto-Injector
- Dosage form
- Kit
- Route
- Intramuscular
- Packs
- 1 kit
- Marketing authorisation holder
- Meridian Medical Technologies
- Manufacturer
- Meridian Medical Technologies
- Origin register
- US FDA, United States
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 January 2002
- Identifiers
- NDC 11704-777Application NDA021175
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 kit in 1 carton * .7 mL in 1 syringe, glass * 2 mL in 1 syringe, glass | 11704-777-01 | Meridian Medical Technologies | 17 January 2002 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 17 January 2002 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Atropine and Pralidoxime kit.
Clinical summary
Atropine and Pralidoxime is a fixed-dose combination medicine indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds). MedsAcross supplies Atropine and Pralidoxime for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Atropine and PralidoximeFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- US FDA NDC directory · Checked 12 November 2026
- DuoDote prescribing information (Meridian Medical Technologies) · U.S. National Library of Medicine, DailyMed
Need ATNAA atropine and pralidoxime chloride Auto-Injector kit for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.